Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
Both the dose and the intensity of longitudinal use of glucocorticoid (GC) are associated with the risk of adverse events (AE) among a nationwide Asian systemic lupus erythematosus (SLE) cohort, according to a recent study.
Treatment with belimumab in Asian patients with systemic lupus erythematosus (SLE) appears to yield significant improvements in disease activity, with a corticosteroid-sparing effect and no new safety signals emerging, according to the results of a phase III trial.
Rheumatic diseases, particularly rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, psoriatic arthritis, and osteoarthritis, appear to pose an increased risk of dementia, a study has reported.
Atacicept demonstrates efficacy in systemic lupus erythematosus (SLE), reducing disease activity and severe flare while having an acceptable safety profile, especially in patients with high disease activity and serologically active disease, according to results from the phase IIb, multicentre ADDRESS II trial.
Patients with systemic lupus erythematosus (SLE) are prone to have cognitive impairment (CI), and the Montreal Cognitive Assessment (MoCA) appears to be a useful tool for detecting CI in SLE, according to a recent study. In addition, CI is less likely to occur in patients with more years of education.
Patients with systemic lupus erythematosus (SLE), compared to those without, have an increased risk of mortality after the first month following an ischaemic stroke, a recent study has found. In addition, functionality becomes poorer at 3 months.
Hydroxychloroquine provides significant immunomodulatory benefits to patients with systemic lupus erythematosus, with a study showing that the drug is associated with a mean reduction of 24.397 mg/dL in serum low-density lipid level.
Hospitalization, as well as rehospitalization within a short period of time, is common among patients with systemic lupus erythematosus (SLE), which is often caused by active SLE or infection, a recent study has found.
Prolonged repetitive physical work such as those tasks associated with construction, for example, increases the risk of developing rheumatoid arthritis (RA), according to the results of a population-based case-control Swedish study presented during the European League Against Rheumatism (EULAR) annual congress held recently in London, England.
A biodegradable nanoparticle delivery system loaded with methotrexate and targeted to inflamed synovial tissue halted the inflammatory process in rat models of rheumatoid arthritis compared to standard free methotrexate therapy.
In patients with type 2 diabetes mellitus (T2DM), advanced glycation end products play a role in bone fragility, according to a new study presented at the recently concluded 5th Scientific Meeting of the Asian Federation of Osteoporosis Societies (AFOS 2017).